IL103070A - תכשירי רוקחות המכילים חומר טראמדוליואחד מהחומרים קודאין, אוקסיקודון אוהידרוקודון - Google Patents

תכשירי רוקחות המכילים חומר טראמדוליואחד מהחומרים קודאין, אוקסיקודון אוהידרוקודון

Info

Publication number: IL103070A
Authority: IL; Israel
Prior art keywords: tramadol; pharmaceutical composition; codeine; oxycodone; hydrocodone
Prior art date: 1991-09-06

Application number

IL10307092A

Other languages

English (en)

Other versions

IL103070A0 (en

Original Assignee

Mcneilab Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-09-06

Filing date

1992-09-06

Publication date

1996-10-16

1992-09-06 Application filed by Mcneilab Inc filed Critical Mcneilab Inc

1993-02-21 Publication of IL103070A0 publication Critical patent/IL103070A0/xx

1996-10-16 Publication of IL103070A publication Critical patent/IL103070A/he

Links

TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 title claims abstract description 69
TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 title claims abstract description 67
229960004380 tramadol Drugs 0.000 title claims abstract description 67
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 title claims abstract description 62
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 title claims abstract description 55
229960004126 codeine Drugs 0.000 title claims abstract description 31
229960002085 oxycodone Drugs 0.000 title claims abstract description 31
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 title claims abstract description 30
XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 title claims abstract description 25
LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 title claims abstract description 24
229960000240 hydrocodone Drugs 0.000 title claims abstract description 24
LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 title claims abstract description 24
239000000463 material Substances 0.000 title claims abstract description 21
239000008194 pharmaceutical composition Substances 0.000 title claims description 20
230000000144 pharmacologic effect Effects 0.000 claims abstract description 5
230000002195 synergetic effect Effects 0.000 claims abstract description 5
230000036407 pain Effects 0.000 claims abstract description 4
PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 claims description 12
229960003107 tramadol hydrochloride Drugs 0.000 claims description 12
238000000034 method Methods 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 46
230000000694 effects Effects 0.000 abstract description 22
206010010774 Constipation Diseases 0.000 abstract description 3
208000004756 Respiratory Insufficiency Diseases 0.000 abstract description 3
206010038678 Respiratory depression Diseases 0.000 abstract description 3
229940127240 opiate Drugs 0.000 abstract description 3
206010012735 Diarrhoea Diseases 0.000 abstract description 2
230000000294 tussive effect Effects 0.000 abstract description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
239000012153 distilled water Substances 0.000 description 16
239000011550 stock solution Substances 0.000 description 16
239000003814 drug Substances 0.000 description 15
229940079593 drug Drugs 0.000 description 14
239000012458 free base Substances 0.000 description 14
238000002360 preparation method Methods 0.000 description 14
230000000202 analgesic effect Effects 0.000 description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
239000000890 drug combination Substances 0.000 description 12
HBXKSXMNNGHBEA-ZBFHGGJFSA-N 1-[(1r,2r)-2-hydroxy-2-(3-methoxyphenyl)cyclohexyl]-n,n-dimethylmethanamine oxide Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)C[N+](C)(C)[O-])=C1 HBXKSXMNNGHBEA-ZBFHGGJFSA-N 0.000 description 11
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 10
UWJUQVWARXYRCG-HIFRSBDPSA-N O-Desmethyltramadol Chemical compound CN(C)C[C@H]1CCCC[C@]1(O)C1=CC=CC(O)=C1 UWJUQVWARXYRCG-HIFRSBDPSA-N 0.000 description 9
230000036592 analgesia Effects 0.000 description 9
239000000243 solution Substances 0.000 description 9
241000699666 Mus <mouse, genus> Species 0.000 description 7
241000699670 Mus sp. Species 0.000 description 7
239000000014 opioid analgesic Substances 0.000 description 7
206010022998 Irritability Diseases 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 6
229940005483 opioid analgesics Drugs 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 4
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
229960004415 codeine phosphate Drugs 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
229940035676 analgesics Drugs 0.000 description 3
239000000730 antalgic agent Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
229940121367 non-opioid analgesics Drugs 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
LLRZWSLBLGNDFM-XFKAJCMBSA-N [(4R,4aS,7aR,12bS)-9-methoxy-3-methyl-7-oxo-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-yl] hydrogen sulfate Chemical compound S(=O)(=O)(O)O[C@@]12CCC([C@H]3[C@]11C=4C(=C(C=CC=4C[C@H]2N(C)CC1)OC)O3)=O LLRZWSLBLGNDFM-XFKAJCMBSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
239000002585 base Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229960005181 morphine Drugs 0.000 description 2
239000003791 organic solvent mixture Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000000725 suspension Substances 0.000 description 2
BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010060800 Hot flush Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
150000001204 N-oxides Chemical class 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
229940127450 Opioid Agonists Drugs 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000011102 Thera Species 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
229960001113 butorphanol Drugs 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000013329 compounding Methods 0.000 description 1
239000000039 congener Substances 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
229960000920 dihydrocodeine Drugs 0.000 description 1
RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
238000005187 foaming Methods 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000005304 joining Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229960001797 methadone Drugs 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000003612 morphinomimetic agent Substances 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000003402 opiate agonist Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229960003617 oxycodone hydrochloride Drugs 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
239000011148 porous material Substances 0.000 description 1
NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
229910000105 potassium hydride Inorganic materials 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000035900 sweating Effects 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Compositions Of Macromolecular Compounds (AREA)
Dental Preparations (AREA)
Fats And Perfumes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

IL10307092A 1991-09-06 1992-09-06 תכשירי רוקחות המכילים חומר טראמדוליואחד מהחומרים קודאין, אוקסיקודון אוהידרוקודון IL103070A (he)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US75592391A	1991-09-06	1991-09-06

Publications (2)

Publication Number	Publication Date
IL103070A0 IL103070A0 (en)	1993-02-21
IL103070A true IL103070A (he)	1996-10-16

Family

ID=25041253

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10307092A IL103070A (he)	1991-09-06	1992-09-06	תכשירי רוקחות המכילים חומר טראמדוליואחד מהחומרים קודאין, אוקסיקודון אוהידרוקודון

Country Status (22)

Country	Link
US (1)	US5468744A (he)
EP (1)	EP0534628B1 (he)
JP (1)	JP3244540B2 (he)
KR (1)	KR100236666B1 (he)
CN (1)	CN1051705C (he)
AT (1)	ATE145330T1 (he)
AU (1)	AU657351B2 (he)
CA (1)	CA2077637C (he)
DE (1)	DE69215316T2 (he)
DK (1)	DK0534628T3 (he)
ES (1)	ES2096726T3 (he)
GR (1)	GR3022515T3 (he)
HU (1)	HU217584B (he)
IL (1)	IL103070A (he)
MX (1)	MX9205106A (he)
MY (1)	MY110317A (he)
NO (1)	NO300197B1 (he)
NZ (1)	NZ244250A (he)
PH (1)	PH31112A (he)
TW (1)	TW271394B (he)
ZA (1)	ZA926732B (he)
ZW (1)	ZW14392A1 (he)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100243956B1 (ko)	1991-09-06	2000-03-02	랄프 알. 팔로	트라마돌 물질 및 아세트아미노펜을 포함하는 통증 치료용 약제학적 조성물
US5968551A (en) *	1991-12-24	1999-10-19	Purdue Pharma L.P.	Orally administrable opioid formulations having extended duration of effect
US5958459A (en) *	1991-12-24	1999-09-28	Purdue Pharma L.P.	Opioid formulations having extended controlled released
US5478577A (en) *	1993-11-23	1995-12-26	Euroceltique, S.A.	Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
NZ260408A (en) *	1993-05-10	1996-05-28	Euro Celtique Sa	Controlled release preparation comprising tramadol
US7740881B1 (en)	1993-07-01	2010-06-22	Purdue Pharma Lp	Method of treating humans with opioid formulations having extended controlled release
IL110014A (en)	1993-07-01	1999-11-30	Euro Celtique Sa	Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) *	1993-07-27	1999-03-09	Euro-Celtique S.A.	Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5891471A (en)	1993-11-23	1999-04-06	Euro-Celtique, S.A.	Pharmaceutical multiparticulates
KR100354702B1 (ko)	1993-11-23	2002-12-28	유로-셀티크 소시에떼 아노뉨	약학조성물의제조방법및서방형조성물
US5843480A (en)	1994-03-14	1998-12-01	Euro-Celtique, S.A.	Controlled release diamorphine formulation
GB9422154D0 (en)	1994-11-03	1994-12-21	Euro Celtique Sa	Pharmaceutical compositions and method of producing the same
US5965161A (en)	1994-11-04	1999-10-12	Euro-Celtique, S.A.	Extruded multi-particulates
US6017963A (en)	1995-11-14	2000-01-25	Euro-Celtique, S.A.	Formulation for intranasal administration
GB9523566D0 (en) *	1995-11-17	1996-01-17	Euro Celtique Sa	Pharmaceutical formulation
DE19601744C2 (de)	1996-01-19	1998-04-16	Gruenenthal Gmbh	Verfahren zur Herstellung der Enantiomeren von O-Demethyltramadol
DE19641576C1 (de) *	1996-10-09	1998-05-07	Gruenenthal Gmbh	Kombinationspräparat enthaltend Tramadol und einen Calcium-Kanal Antagonisten
DE19712398A1 (de) *	1997-03-25	1998-10-01	Gruenenthal Gmbh	Orale Anwendung von (+)-0-Demethyltramadol als Schmerzmittel
DK0996613T3 (da)	1997-07-15	2003-03-03	Russinsky Ltd	Fremstilling af rent cis-tramadol-hydrochlorid
US6156342A (en) *	1998-05-26	2000-12-05	Andex Pharmaceuticals, Inc.	Controlled release oral dosage form
US6608073B1 (en)	1998-10-14	2003-08-19	New Millennium Pharmaceutical Research, Inc.	Intranasal codeine for the rapid suppression of cough and rapid relief of pain
US6806294B2 (en)	1998-10-15	2004-10-19	Euro-Celtique S.A.	Opioid analgesic
DE19918325A1 (de)	1999-04-22	2000-10-26	Euro Celtique Sa	Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US20030118641A1 (en) *	2000-07-27	2003-06-26	Roxane Laboratories, Inc.	Abuse-resistant sustained-release opioid formulation
PL213323B1 (pl)	1999-08-20	2013-02-28	Ortho Mcneil Pharm Inc	Kompozycja farmaceutyczna i jej zastosowanie
DE19940740A1 (de) *	1999-08-31	2001-03-01	Gruenenthal Gmbh	Pharmazeutische Salze
PE20010623A1 (es)	1999-10-05	2001-07-07	Gruenenthal Chemie	Uso de (+)-tramadol y/o o-demetiltramadol para tratamiento de urgencia urinaria incrementada y/o incontinencia urinaria
KR100889069B1 (ko)	1999-10-29	2009-03-17	유로-셀티크 소시에떼 아노뉨	서방성 하이드로코돈 제형
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
EP1313460A2 (en) *	1999-11-09	2003-05-28	Darwin Discovery Limited	Therapeutic use and formulation of (-)-tramadol
AU2738302A (en)	2000-10-30	2002-05-15	Euro Celtique Sa	Controlled release hydrocodone formulations
JP2004517119A (ja) *	2000-12-29	2004-06-10	オトクリトエアクチオネルノエオブスチェストボナウチノ−プロイズボドストベンナヤフィルマ“ペルフトラン”	ガス輸送エマルジョン用の主成分としての第三級ペルフルオロシクロアミンおよびその調製方法
JP4377585B2 (ja)	2001-03-16	2009-12-02	ディーエムアイバイオサイエンシズインコーポレイテッド	射精遅延の方法
RU2196765C2 (ru) *	2001-04-09	2003-01-20	Федеральное государственное унитарное предприятие Новокузнецкий научно-исследовательский химико-фармацевтический институт	Способ выделения и очистки (rr,ss)-2-[(диметиламино)метил]-1-(3-метоксифенил)циклогексанола (трамадола) гидрохлорида
UA81224C2 (uk)	2001-05-02	2007-12-25	Euro Celtic S A	Дозована форма оксикодону та її застосування
US20110104214A1 (en)	2004-04-15	2011-05-05	Purdue Pharma L.P.	Once-a-day oxycodone formulations
WO2003048113A1 (en)	2001-11-30	2003-06-12	Sepracor Inc.	Tramadol analogs and uses thereof
EP1364649A1 (en) *	2002-05-23	2003-11-26	Cilag AG	Adduct of topiramate and tramadol hydrochioride and uses thereof
US20040058946A1 (en) *	2002-07-05	2004-03-25	Buchwald Stephen L.	Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
PL377351A1 (pl) *	2002-12-13	2006-01-23	Cilag Ag	Preparaty o kontrolowanym uwalnianiu zawierające tramadol i topiramat
AU2007225022A1 (en) *	2006-03-15	2007-09-20	Biotech Pharmaceuticals Pty Ltd	Non-codeine opioid analgesic process and formulations
RS55769B1 (sr) *	2007-11-23	2017-07-31	Gruenenthal Gmbh	Kompozicije tapentadola
US20090264454A1 (en) *	2008-04-16	2009-10-22	Nickell Robert P	Combined hydrocodone and analgesic formulation and method
US20100003322A1 (en) *	2008-07-03	2010-01-07	Lai Felix S	Enteric coated hydrophobic matrix formulation
US20100190752A1 (en)	2008-09-05	2010-07-29	Gruenenthal Gmbh	Pharmaceutical Combination
US10702485B2 (en)	2011-07-09	2020-07-07	Syntrix Biosystems Inc.	Compositions and methods for overcoming resistance to tramadol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3652589A (en) *	1967-07-27	1972-03-28	Gruenenthal Chemie	1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
AU2402392A (en) *	1991-08-06	1993-03-02	Byk Gulden Lomberg Chemische Fabrik Gmbh	New anti-diarrheic agents
AU2062892A (en) *	1991-08-16	1993-02-18	Mcneil-Ppc, Inc.	Potentiation of antitussive effect of dextromethorphan

1992
- 1992-09-04 CA CA002077637A patent/CA2077637C/en not_active Expired - Lifetime
- 1992-09-04 ZW ZW14392A patent/ZW14392A1/xx unknown
- 1992-09-04 DK DK92308076.6T patent/DK0534628T3/da active
- 1992-09-04 ES ES92308076T patent/ES2096726T3/es not_active Expired - Lifetime
- 1992-09-04 EP EP92308076A patent/EP0534628B1/en not_active Expired - Lifetime
- 1992-09-04 HU HU9202845A patent/HU217584B/hu unknown
- 1992-09-04 MY MYPI92001591A patent/MY110317A/en unknown
- 1992-09-04 NO NO923453A patent/NO300197B1/no not_active IP Right Cessation
- 1992-09-04 AU AU22185/92A patent/AU657351B2/en not_active Expired
- 1992-09-04 MX MX9205106A patent/MX9205106A/es unknown
- 1992-09-04 ZA ZA926732A patent/ZA926732B/xx unknown
- 1992-09-04 AT AT92308076T patent/ATE145330T1/de active
- 1992-09-04 DE DE69215316T patent/DE69215316T2/de not_active Expired - Lifetime
- 1992-09-04 PH PH44893A patent/PH31112A/en unknown
- 1992-09-05 KR KR1019920016227A patent/KR100236666B1/ko not_active Expired - Lifetime
- 1992-09-05 CN CN92111382A patent/CN1051705C/zh not_active Expired - Lifetime
- 1992-09-06 IL IL10307092A patent/IL103070A/he not_active IP Right Cessation
- 1992-09-07 NZ NZ244250A patent/NZ244250A/en not_active IP Right Cessation
- 1992-09-07 JP JP26269392A patent/JP3244540B2/ja not_active Expired - Lifetime
- 1992-11-10 TW TW081108967A patent/TW271394B/zh not_active IP Right Cessation
1994
- 1994-06-30 US US08/268,382 patent/US5468744A/en not_active Expired - Lifetime
1997
- 1997-02-12 GR GR960403334T patent/GR3022515T3/el unknown

Also Published As

Publication number	Publication date
NO300197B1 (no)	1997-04-28
US5468744A (en)	1995-11-21
CA2077637C (en)	2007-01-09
JP3244540B2 (ja)	2002-01-07
EP0534628B1 (en)	1996-11-20
CA2077637A1 (en)	1993-03-07
IL103070A0 (en)	1993-02-21
MY110317A (en)	1998-04-30
ZA926732B (en)	1994-03-04
TW271394B (he)	1996-03-01
DE69215316T2 (de)	1997-03-20
PH31112A (en)	1998-02-23
CN1051705C (zh)	2000-04-26
HU9202845D0 (en)	1992-11-30
HUT63556A (en)	1993-09-28
DE69215316D1 (de)	1997-01-02
NO923453L (no)	1993-03-08
GR3022515T3 (en)	1997-05-31
KR100236666B1 (ko)	2000-03-02
JPH06107540A (ja)	1994-04-19
HU217584B (hu)	2000-02-28
DK0534628T3 (da)	1996-12-09
CN1071835A (zh)	1993-05-12
ATE145330T1 (de)	1996-12-15
ZW14392A1 (en)	1994-05-11
EP0534628A1 (en)	1993-03-31
ES2096726T3 (es)	1997-03-16
MX9205106A (es)	1993-05-01
AU657351B2 (en)	1995-03-09
KR930005617A (ko)	1993-04-20
NO923453D0 (no)	1992-09-04
NZ244250A (en)	1994-01-26
AU2218592A (en)	1993-03-11

Legal Events

Date	Code	Title
1997-03-18	FF	Patent granted
1997-07-13	KB	Patent renewed
1999-01-26	KB	Patent renewed
2002-11-10	KB	Patent renewed
2006-10-30	KB	Patent renewed
2010-11-30	KB	Patent renewed
2013-04-30	EXP	Patent expired

Publication	Publication Date	Title
US5468744A (en)	1995-11-21	Composition comprising a tramadol material and any of codeine, oxycodone or hydrocodone and their use
EP0566709B1 (en)	1998-08-12	Composition comprising a tramadol compound and acetaminophen, and its use
EP0532348B1 (en)	1996-01-10	A tramadol N-oxide material, enantiomers and compositions thereof, and their use
EP0546676B1 (en)	2004-12-22	Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
KR100758609B1 (ko)	2007-09-13	트라마돌 화합물 및 항경련 약물을 포함하는 조성물
JP2003521470A (ja)	2003-07-15	ベンラファキシンの誘導体とその調製および使用方法
JP2003501344A (ja)	2003-01-14	（＋）−ベンラファキシン誘導体並びにその製造方法および使用方法
NZ244507A (en)	1994-09-27	Pharmaceutical compositions of a tramadol material and acetaminophen
JPH04503216A (ja)	1992-06-11	癲癇およびコカイン嗜癖治療用の５―アミノカルボニル―５Ｈ―ジベンゾ〔ａ，ｄ〕シクロヘプテン―５，１０―イミン
HK1139380A (en)	2010-09-17	Derivatives of venlafaxine and methods of preparing and using the same